Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 For Treatment Of Duchenne Muscular Dystrophy In People With Mutations Amenable To Exon 44 Skipping
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences has received FDA Orphan Drug Designation for AOC 1044, a treatment for Duchenne Muscular Dystrophy (DMD) in people with mutations amenable to exon 44 skipping. AOC 1044 is currently in Phase 1/2 EXPLORE44™ clinical trial. Results from the healthy volunteer portion of the trial are expected in Q4 2023. AOC 1044 received FDA Fast Track designation in April 2023.
August 15, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity Biosciences' AOC 1044, a treatment for Duchenne Muscular Dystrophy, has received FDA Orphan Drug Designation. This could potentially boost the company's stock in the short term.
The FDA Orphan Drug Designation is granted to drugs that are intended for the safe and effective treatment of rare diseases. This designation could potentially lead to expedited review and approval, which could positively impact Avidity Biosciences' stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100